Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-1.61Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: -0.66%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Longeveron's progress, with strong revenue growth and regulatory advancements highlighted. However, challenges like enrollment delays in clinical trials and anticipated increases in future expenses were also noted. The call reflected cautious optimism about Lomecel-B's potential, supported by robust clinical data and regulatory designations, though future financial and strategic uncertainties remain.Company Guidance
During the Longeveron 2024 Full Year Financial Results Conference Call, the company provided detailed guidance on its clinical and financial progress. Longeveron reported a significant increase in revenue to $2.4 million, up 237% from 2023, mainly driven by participant demand for its frailty and cognitive impairment registry trial in the Bahamas and new contract manufacturing revenue. The company emphasized its dedication to advancing its stem cell therapy, Lomecel-B, highlighting progress in its Phase IIb ELPIS II trial for hypoplastic left heart syndrome (HLHS), which achieved over 90% enrollment and is expected to complete enrollment by the second quarter of 2025. Longeveron also outlined its path to a potential biologics license application (BLA) submission in 2026, contingent on positive results from the ELPIS II trial. Additionally, the company is focusing on its Alzheimer's disease program, having received both regenerative medicine advanced therapy (RMAT) designation and fast track designation from the FDA. Financially, Longeveron decreased its net loss by 25% to approximately $16 million and reported cash and cash equivalents of $19.2 million, providing a runway into the fourth quarter of 2025. The company anticipates accelerated operating expenses in 2025 as it ramps up BLA-enabling activities.Significant Revenue Growth
Revenues for 2024 were $2.4 million, up $1.7 million or 237% compared to 2023, driven by increased participant demand and new contract manufacturing revenue.
Regulatory Advancement for HLHS Program
The FDA confirmed that the ELPIS II study is pivotal and acceptable for BLA submission for traditional approval, accelerating the potential regulatory path for Lomecel-B.
FDA Designations for Alzheimer's Program
Lomecel-B received both RMAT and fast track designations for the treatment of mild Alzheimer's disease, based on positive Phase IIa data.
Cost Management and Reduced Expenses
Total operating expenses for 2024 declined 13% year-over-year, with G&A expenses decreasing 16% and R&D expenses decreasing 10%.
Strong Cash Position
Cash and cash equivalents as of December 31, 2024, were $19.2 million, providing funding into Q4 2025.
---
LGVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LGVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $1.52 | $1.38 | -9.21% |
| Nov 12, 2024 | $2.30 | $2.12 | -7.83% |
| Aug 14, 2024 | $2.61 | $2.46 | -5.75% |
| May 14, 2024 | $1.39 | $1.34 | -3.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Longeveron (LGVN) report earnings?
Longeveron (LGVN) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Longeveron (LGVN) earnings time?
Longeveron (LGVN) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGVN EPS forecast?
LGVN EPS forecast for the fiscal quarter 2025 (Q1) is -0.33.
---